Kalvista Pharmaceuticals (KALV) Downgraded to Hold at BidaskClub

BidaskClub lowered shares of Kalvista Pharmaceuticals (NASDAQ:KALV) from a buy rating to a hold rating in a research report sent to investors on Wednesday, BidAskClub reports.

A number of other research firms also recently issued reports on KALV. Zacks Investment Research downgraded shares of Kalvista Pharmaceuticals from a strong-buy rating to a hold rating in a research note on Thursday, February 21st. Needham & Company LLC initiated coverage on shares of Kalvista Pharmaceuticals in a research note on Wednesday, March 20th. They issued a buy rating and a $35.00 price target for the company. ValuEngine raised shares of Kalvista Pharmaceuticals from a hold rating to a buy rating in a research note on Monday, February 4th. Finally, Roth Capital increased their price target on shares of Kalvista Pharmaceuticals from $25.00 to $30.00 and gave the stock a buy rating in a research note on Wednesday, May 15th. Two equities research analysts have rated the stock with a hold rating and six have given a buy rating to the company. The company has an average rating of Buy and an average price target of $30.60.

Kalvista Pharmaceuticals stock opened at $23.89 on Wednesday. The stock has a market cap of $412.03 million, a PE ratio of -15.61 and a beta of 2.32. Kalvista Pharmaceuticals has a 1-year low of $7.73 and a 1-year high of $34.92.

Kalvista Pharmaceuticals (NASDAQ:KALV) last released its quarterly earnings results on Thursday, March 14th. The specialty pharmaceutical company reported ($0.23) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($0.45) by $0.22. Kalvista Pharmaceuticals had a negative net margin of 70.08% and a negative return on equity of 19.12%. The company had revenue of $3.89 million during the quarter, compared to the consensus estimate of $3.97 million. As a group, research analysts predict that Kalvista Pharmaceuticals will post -1.43 EPS for the current year.

In other Kalvista Pharmaceuticals news, major shareholder Svlsf Iv, Llc sold 43,378 shares of the firm’s stock in a transaction that occurred on Monday, March 4th. The shares were sold at an average price of $22.91, for a total transaction of $993,789.98. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, major shareholder Venrock Healthcare Capital Par sold 500,000 shares of the firm’s stock in a transaction that occurred on Monday, March 18th. The shares were sold at an average price of $28.75, for a total transaction of $14,375,000.00. The disclosure for this sale can be found here. Insiders have sold 901,521 shares of company stock valued at $25,597,568 in the last ninety days. Insiders own 38.40% of the company’s stock.

Hedge funds and other institutional investors have recently made changes to their positions in the business. Flinton Capital Management LLC bought a new position in shares of Kalvista Pharmaceuticals during the fourth quarter valued at approximately $26,000. Ramsey Quantitative Systems bought a new position in shares of Kalvista Pharmaceuticals during the fourth quarter valued at approximately $35,000. Bank of Montreal Can bought a new position in shares of Kalvista Pharmaceuticals during the fourth quarter valued at approximately $90,000. Marshall Wace North America L.P. bought a new position in shares of Kalvista Pharmaceuticals during the first quarter valued at approximately $175,000. Finally, Morgan Stanley increased its stake in shares of Kalvista Pharmaceuticals by 780.7% during the first quarter. Morgan Stanley now owns 7,486 shares of the specialty pharmaceutical company’s stock valued at $214,000 after purchasing an additional 6,636 shares in the last quarter. 79.52% of the stock is owned by institutional investors and hedge funds.

About Kalvista Pharmaceuticals

KalVista Pharmaceuticals, Inc, a clinical stage pharmaceutical company, discovers, develops, and commercializes small molecule protease inhibitors. The company's product portfolio comprises small molecule plasma kallikrein inhibitors targeting hereditary angioedema (HAE) and diabetic macular edema (DME); and oral plasma kallikrein inhibitors.

Featured Story: Stop Order Uses For Individual Investors

Analyst Recommendations for Kalvista Pharmaceuticals (NASDAQ:KALV)

Receive News & Ratings for Kalvista Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kalvista Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.